Detalhe da pesquisa
1.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Haematologica
; 108(8): 2091-2100, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36632738
2.
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.
Hematol Oncol
; 39(3): 326-335, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33739461
3.
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Eur J Haematol
; 106(4): 493-499, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33378569
4.
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
Am J Hematol
; 98(9): E237-E240, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37382471
5.
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
Am J Hematol
; 98(2): E24-E27, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36349541
6.
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report.
Blood
; 136(6): 763-766, 2020 08 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32559271
7.
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.
Am J Hematol
; 97(3): E95-E99, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34904743
8.
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.
Hematol Oncol
; 39(4): 570-574, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34258787
9.
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
Am J Hematol
; 96(5): E168-E171, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33580969
10.
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
Am J Hematol
; 96(8): E306-E310, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33989438
11.
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Am J Hematol
; 96(8): E269-E272, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33878220
12.
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2).
Haematologica
; 105(11): 2671-2674, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33131259
13.
The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.
J Basic Clin Physiol Pharmacol
; 34(3): 401-404, 2023 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37040263
14.
Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice.
Cancers (Basel)
; 15(22)2023 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38001657
15.
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.
Cancers (Basel)
; 14(1)2021 Dec 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35008372
16.
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study.
Blood Adv
; 6(13): 3875-3878, 2022 07 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35789375
17.
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
Leukemia
; 35(1): 235-238, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32286543
18.
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab.
Blood Cancer J
; 10(9): 92, 2020 09 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32938904
19.
A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma.
Clin Lymphoma
; 5(1): 50-5, 2004 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15245608
20.
Treatment of elderly Hodgkin's lymphoma patients. The experience of the Italian Lymphoma Intergroup.
Tumori
; 88(1 Suppl 1): S29-31, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-11989917